Clinical application of FOLFIRINOX regimen for pancreatic cancer

doi:10.3760/cma.j.issn.1673-422X.2017.11.018

Abstract

Abstract: Clinical studies have confirmed the FOLFIRINOX regimen (oxaliplatin+irinotecan+fluorouracil+leucovorin) is an effective regimen for advanced pancreatic cancer patients with good performance status. Current clinical studies on FOLFIRINOX regimen mainly include neoadjuvant therapy for unresectable and borderline resectable pancreatic cancer and firstline therapy for locally advanced pancreatic cancer and metastatic pancreatic cancer, which improved patient′s surgical resection opportunities and survival. In addition, the toxicity, safety of FOLFIRINOX regimen and effective population selection for FOLFIRINOX regimen are also the problems concerned by researchers.

Key words: Pancreatic neoplasms, Drug therapy, FOLFIRINOX regimen

于兰，张小涛，李进英，王玉. Clinical application of FOLFIRINOX regimen for pancreatic cancer[J]. Journal of International Oncology, 2017, 44(11): 874-878.

References

［1］ Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017［J］. CA Cancer J Clin, 2017, 67(1): 7-30. DOI: 10.3322/caac.21387. ［2］ Rahib L, Smith BD, Aizenberg R, et al. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States［J］. Cancer Res, 2014, 74(11): 2913-2921. DOI: 10.1158/0008-5472.CAN-14-0155. ［3］ Stathis A, Moore MJ. Advanced pancreatic carcinoma: current treatment and future challenges［J］. Nat Rev Clin Oncol, 2010, 7(3): 163-172. DOI: 10.1038/nrclinonc.2009.236. ［4］ Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer［J］. N Engl J Med, 2011, 364(19): 1817-1825. DOI: 10.1056/NEJMoa1011923. ［5］ Gillen S, Schuster T, Meyer Zum Büschenfelde C, et al. Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages［J］. PLoS Med, 2010, 7(4): e1000267. DOI: 10.1371/journal.pmed.1000267. ［6］ Schorn S, Demir IE, Reyes CM, et al. The impact of neoadjuvant therapy on the histopathological features of pancreatic ductal adenocarcinoma—a systematic review and metaanalysis［J］. Cancer Treat Rev, 2017, 55: 96-106. DOI: 10.1016/j.ctrv.2017.03.003. ［7］ Katz MH, Shi Q, Ahmad SA, et al. Preoperative modified FOLFIRINOX treatment followed by capecitabinebased chemoradiation for borderline resectable pancreatic cancer: alliance for clinical trials in oncology trial A021101［J］. JAMA Surg, 2016, 151(8): e161137. DOI: 10.1001/jamasurg.2016.1137. ［8］ Khushman M, Dempsey N, Maldonado JC, et al. Full dose neoadjuvant FOLFIRINOX is associated with prolonged survival in patients with locally advanced pancreatic adenocarcinoma［J］. Pancreatology, 2015, 15(6): 667-673. DOI: 10.1016/j.pan.2015.08.010. ［9］ Hackert T, Sachsenmaier M, Hinz U, et al. Locally advanced pancreatic cancer: neoadjuvant therapy with folfirinox results in resectability in 60% of the patients［J］. Ann Surg, 2016, 264(3): 457-463. DOI: 10.1097/SLA.0000000000001850. ［10］ Pietrasz D, Marthey L, Wagner M, et al. Pathologic major response after FOLFIRINOX is prognostic for patients secondary resected for borderline or locally advanced pancreatic adenocarcinoma: an AGEOFRENCH, prospective, multicentric cohort［J］. Ann Surg Oncol, 2015, 22 Suppl 3: S11961205. DOI: 10.1245/s10434-015-4783-x. ［11］ Faris JE, Blaszkowsky LS, McDermott S, et al. FOLFIRINOX in locally advanced pancreatic cancer: the Massachusetts general hospital cancer center experience［J］. Oncologist, 2013, 18(5): 543-548. DOI: 10.1634/theoncologist.2012-0435. ［12］ Marthey L, SaCunha A, Blanc JF, et al. FOLFIRINOX for locally advanced pancreatic adenocarcinoma: results of an AGEO multicenter prospective observational cohort［J］. Ann Surg Oncol, 2015, 22(1): 295-301. DOI: 10.1245/s10434-014-3898-9. ［13］ Mellon EA, Hoffe SE, Springett GM, et al. Longterm outcomes of induction chemotherapy and neoadjuvant stereotactic body radiotherapy for borderline resectable and locally advanced pancreatic adenocarcinoma［J］. Acta Oncol, 2015, 54(7): 979-985. DOI: 10.3109/0284186X.2015.1004367. ［14］ Suker M, Beumer BR, Sadot E, et al. FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patientlevel metaanalysis［J］. Lancet Oncol, 2016, 17(6): 801810. DOI: 10.1016/S1470-2045(16)00172-8. ［15］ Marthey L, SaCunha A, Blanc JF, et al. FOLFIRINOX for locally advanced pancreatic adenocarcinoma: results of an AGEO multicenter prospective observational cohort［J］. Ann Surg Oncol, 2015, 22(1): 295301. DOI: 10.1245/s1043401438989. ［16］白雪莉, 苏日嘎, 马涛, 等. 改良FOLFIRINOX方案治疗进展期胰腺癌单中心经验［J］. 中华外科杂志, 2016, 54(4): 270-275. DOI: 10.3760/cma.j.issn.0529-5815.2016.04.006. ［17］ Arslan C, Yalcin S. Current and future systemic treatment options in metastatic pancreatic cancer［J］. J Gastrointest Oncol, 2014, 5(4): 280-295. DOI: 10.3978/j.issn.20786891.2014.030. ［18］ Cinar P, Ko AH. Best practices for the treatment of metastatic pancreatic adenocarcinoma: the therapeutic landscape in 2017［J］. Chin Clin Oncol, 2017, 6(3): 29. DOI: 10.21037/cco.2017.06.13. ［19］ Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase Ⅲ trial of the National Cancer Institute of Canada Clinical Trials Group［J］. J Clin Oncol, 2007, 25(15): 1960-1966. DOI: 10.1200/JCO.2006.07.9525. ［20］ Zahir MN, Jabbar AA. Metastatic pancreatic carcinoma and experience with FOLFIRINOXa cross sectional analysis from a developing country［J］. Asian Pac J Cancer Prev, 2015, 16(14): 60016006. ［21］ Kim R. FOLFIRINOX: a new standard treatment for advanced pancreatic cancer?［J］ Lancet Oncol, 2011, 12(1): 8-9. DOI: 10.1016/S1470-2045(10)70237-0. ［22］ Ghorani E, Wong HH, Hewitt C, et al. Safety and efficacy of modified FOLFIRINOX for advanced pancreatic adenocarcinoma: a UK singlecentre experience［J］. Oncology, 2015, 89(5): 281-287. DOI: 10.1159/000439171. ［23］ Orlandi A, Calegari MA, Martini M, et al. Gemcitabine versus FOLFIRINOX in patients with advanced pancreatic adenocarcinoma hENT1positive: everything was not too bad back when everything seemed worse［J］. Clin Transl Oncol, 2016, 18(10): 988-995. DOI: 10.1007/s120940151471z. ［24］ Capello M, Lee M, Wang H, et al. Carboxylesterase 2 as a determinant of response to irinotecan and neoadjuvant FOLFIRINOX therapy in pancreatic ductal adenocarcinoma［J］. J Natl Cancer Inst, 2015, 107(8). pii: ajv132. DOI: 10.1093/jnci/djv132.

[1]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu. Research progress on intestinal flora and non-surgical treatment of the colorectal cancer [J]. Journal of International Oncology, 2024, 51(6): 376-381.
[2]	Yue Hongyun, Zhang Baihong. Differentiation therapies in human cancers [J]. Journal of International Oncology, 2024, 51(2): 109-113.
[3]	Jin Xudong, Chen Zhongjian, Mao Weimin. Research progress on the role of MTAP in malignant mesothelioma [J]. Journal of International Oncology, 2024, 51(2): 99-104.
[4]	Li Chenxi, Zhao Hongwei. Prognosis and influencing factors of platinum sensitive recurrent ovarian cancer treated by secondary cytoreduction surgery in patients with unsatisfactory primary cytoreduction surgery [J]. Journal of International Oncology, 2023, 50(6): 342-347.
[5]	Li Qingshan, Xie Xin, Zhang Nan, Liu Shuai. Research progress on the application of combining radiotherapy and systemic therapy in breast cancer [J]. Journal of International Oncology, 2023, 50(6): 362-367.
[6]	Kui Guoju, Huang Jiangbin, Zhang Wenhua, Yang Limin. Effect of regional lymph node diameter on postoperative recurrence in pancreatic cancer patients [J]. Journal of International Oncology, 2023, 50(10): 608-613.
[7]	Chen Yi, Han Liang, Cai Li. Multivariate analysis of chemotherapy induced oral mucositis in patients with head and neck tumors [J]. Journal of International Oncology, 2022, 49(9): 521-525.
[8]	Chu Xuelei, Mao Yun, Xue Peng, Li Linlu, Chen Meichi, Yuan Chunsheng, Qin Xiaoyan, Zhu Shijie. Effects of chemotherapy dose intensity on short-term efficacy in patients with advanced colon cancer： a study based on real-world data [J]. Journal of International Oncology, 2022, 49(7): 408-415.
[9]	Tang Lin, Xiang Mingyue, Zhang Jianbo, Wang Lili, Gong Heyi, Han Dali. Clinical efficacy and safety of camrelizumab combined with apatinib and chemotherapy as second-line or later therapy in the treatment of HER-2 negative advanced gastric cancer [J]. Journal of International Oncology, 2022, 49(5): 276-281.
[10]	Gao Shile, Lu Donghui, Liu Meiqin, Xu Xingjun, Ma Huan, Zhang Yu. Clinical efficacy and optimal dose of apatinib combined with chemotherapy in patients with advanced non-small cell lung cancer [J]. Journal of International Oncology, 2022, 49(3): 140-145.
[11]	Lao Zheng, Tu Wenyong, Xu Xuanli, Zhang Lin, Shao Ziyang, Shi Huifeng. Nimotuzumab combined with definitive radiotherapy for inoperable locally advanced oral and maxillofacial squamous cell carcinoma [J]. Journal of International Oncology, 2022, 49(11): 665-670.
[12]	Luo Liyun, Lai Canhui, Liang Renpei, Yang Aiwu, Lin Zhimin. Correlation between the expressions of miR-524-5p and SOX9 in advanced gastric cancer and their influences on chemotherapy efficacy and prognosis [J]. Journal of International Oncology, 2022, 49(1): 45-50.
[13]	Long Xin, Wu Han, Peng Jin, Zhou Fuxiang. Systemic therapy of advanced biliary tract cancer [J]. Journal of International Oncology, 2021, 48(5): 302-307.
[14]	Yan Zhiying, Mao Yifeng, Zhu Yingwei, Xu Kequn. Role of heterogeneity of cancer-associated fibroblasts in targeted therapy of pancreatic cancer [J]. Journal of International Oncology, 2021, 48(5): 308-312.
[15]	Song Yang, Wang Bin, Xiao He, Chen Chuan, Wang Ge, Geng Mingying. Predictive value of tumor regression rate after induction chemotherapy for survival of patients with locally advanced nasopharyngeal carcinoma [J]. Journal of International Oncology, 2021, 48(3): 156-163.